Abstract
Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78% and 71%, and the 5- and 10-year disease-free intervals were 68% and 64%, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 537-543 |
| Number of pages | 7 |
| Journal | Thoracic and Cardiovascular Surgeon |
| Volume | 54 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Dec 2006 |
| Externally published | Yes |
Fingerprint
Keywords
- Non-small cell lung cancer
- Thoracic surgery
- Tumor size
- Tumor volume
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer. / Tsai, C. H.; Lin, C. M.; Hsieh, C. C.; Hsu, W. H.; Wang, H. W.; Wang, Liang Shun.
In: Thoracic and Cardiovascular Surgeon, Vol. 54, No. 8, 12.2006, p. 537-543.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer
AU - Tsai, C. H.
AU - Lin, C. M.
AU - Hsieh, C. C.
AU - Hsu, W. H.
AU - Wang, H. W.
AU - Wang, Liang Shun
PY - 2006/12
Y1 - 2006/12
N2 - Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78% and 71%, and the 5- and 10-year disease-free intervals were 68% and 64%, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.
AB - Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78% and 71%, and the 5- and 10-year disease-free intervals were 68% and 64%, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.
KW - Non-small cell lung cancer
KW - Thoracic surgery
KW - Tumor size
KW - Tumor volume
UR - http://www.scopus.com/inward/record.url?scp=34247169980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247169980&partnerID=8YFLogxK
U2 - 10.1055/s-2006-924479
DO - 10.1055/s-2006-924479
M3 - Article
VL - 54
SP - 537
EP - 543
JO - Thoracic and Cardiovascular Surgeon
JF - Thoracic and Cardiovascular Surgeon
SN - 0171-6425
IS - 8
ER -